Vogenx Inc Common Stock Total Liabilities
Vogenx Inc Common Stock total liabilities. Based on the latest financial reports, Vogenx Inc Common Stock (VOGX) has total liabilities worth $3.19 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See VOGX working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Total Liabilities of Vogenx Inc Common Stock (2024–2025)
Total liabilities of Vogenx Inc Common Stock from 2024 to 2025. This chart illustrates how Vogenx Inc Common Stock's total liabilities have evolved over time, based on quarterly financial data.
Vogenx Inc Common Stock Competitors by Total Liabilities
The table below lists competitors of Vogenx Inc Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Xperi Corp
NYSE:XPER
|
USA | $536.31 Million |
|
Sichuan Golden Summit Group Joint Stock Co Ltd
SHG:600678
|
China | CN¥1.21 Billion |
|
EnviTec Biogas AG
XETRA:ETG
|
Germany | €237.48 Million |
|
QST International
TWO:8349
|
Taiwan | NT$14.47 Billion |
|
Silvia, Inc.
NASDAQ:SVIA
|
USA | $95.66 Million |
|
Tredegar Corporation
NYSE:TG
|
USA | $179.85 Million |
|
CERRO DE PASCO RES
F:N8HP
|
Germany | €6.11 Million |
|
PharmaEngine
TWO:4162
|
Taiwan | NT$112.86 Million |
Liability Composition Analysis (2024–2025)
This chart breaks down Vogenx Inc Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see balance sheet size of Vogenx Inc Common Stock.
Liquidity & Leverage Metrics
Vogenx Inc Common Stock Total Liabilities Ratios Explained
Vogenx Inc Common Stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.44 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.79 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 2.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vogenx Inc Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vogenx Inc Common Stock (2024–2025)
The table below shows the annual total liabilities of Vogenx Inc Common Stock from 2024 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.60 Million | +247.30% |
| 2024-12-31 | $460.81K | -- |
About Vogenx Inc Common Stock
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857. It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party pay… Read more